Corcept Therapeutics reported a quarterly loss of $0.30 per share, exactly in line with the Zacks Consensus Estimate. That compares with earnings of $0.17 per share in the same quarter last year, indicating a year-over-year deterioration in profitability. The release is largely in line with expectations and is unlikely to drive a major market move.
Corcept Therapeutics reported a quarterly loss of $0.30 per share, exactly in line with the Zacks Consensus Estimate. That compares with earnings of $0.17 per share in the same quarter last year, indicating a year-over-year deterioration in profitability. The release is largely in line with expectations and is unlikely to drive a major market move.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
-0.05
Ticker Sentiment
